Table 3.

Phase 3 trials in relapsed and/or refractory MM: convenience

Regimen (reference)Route of administrationDosing scheduleHospital/clinic visitAdministration time
KRd (25)IVCycle 1-12: days 1, 2, 8, 9, 15, and 16 of 28-d cycle. Cycle 13-18: days 1, 2, 15, and 16 of 28-d cycle2/wk (3 wk on/1 wk off)>30 min + pretreatment hydration
IRd (28)PODays 1, 8, and 15 of 28-d cycleEvery 4 wk0 h
Rd + elotuzumab (27)IVDays 1, 8, 15, and 22 of 28-d cycle (cycles 1 and 2), then days 1 and 15 (cycle 3+)1/wk for 8 wk, then every 2 wk5 h; need premedication
DRd (29)IVDays 1, 8, 15m and 22 of 28-d cycle (cycle 1 and 2), days 1 and 15 (cycle 3-6), then every 4 wk thereafter1/wk for 8 wk, every 2 wk for 16 wk, then every 4 wk6.5 h for the first infusion and 3.5 h for subsequent infusions; need premedication
Vd + panobinostat (34)PO (+ bortezomib IV)Panobinostat: days 1, 3, 4, 8, 10, and 12 of 21-d cycle; bortezomib: days 1, 4, 8, and 112/wk (2 wk on/1 wk off)∼1 h for bortezomib
DVd (33)IV (+ bortezomib SC)Daratumumab: days 1, 8, and 15 of 21-d cycle (cycle 1-3), every 3 wk (cycle 4-8), then every 4 wk; bortezomib: days 1, 4, 8, and 114-5 visits by 21-d cycle6.5 h for the first infusion and 3.5 h for subsequent infusions; need premedication
Kd (31)IVCarfilzomib: days 1, 2, 8, 9, 15, and 16 of 28-d cycle2/wk (3 wk on/1 wk off)>30 min + pretreatment hydration
  • PO, per os; SC, subcutaneous.